Literature DB >> 2191189

Effects of intraperitoneal versus subcutaneous insulin administration on lipoprotein metabolism in type I diabetes.

G Ruotolo1, P Micossi, G Galimberti, M C Librenti, G Petrella, S Marcovina, G Pozza, B V Howard.   

Abstract

In order to compare the effects of intraperitoneal (IP) versus subcutaneous (SC) insulin delivery on plasma lipoproteins, lipoprotein cholesterol, triglycerides, and very-low-density lipoprotein (VLDL) metabolism were compared in five type I diabetic patients while they were receiving continuous IP insulin (CIPII) or continuous subcutaneous insulin infusion (CSII). Each therapy regimen was of at least 1 month duration, and patients were treated in random order. Mean daily plasma insulin was lower on CIPII compared with CSII. CIPII was associated with lower VLDL triglycerides and VLDL apolipoprotein (apo) B, and higher high-density lipoprotein (HDL) and HDL3 cholesterol. The decreased VLDL on CIPII appeared to be the result of both decreased production and increased clearance of VLDL apo B. The results suggest that the more physiologic route of insulin therapy (CIPII) is associated with lipoprotein profiles of lower atherogenic potential.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2191189     DOI: 10.1016/0026-0495(90)90025-8

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  3 in total

1.  Effect of thyroid hormone binding proteins on insulin receptor binding of B1-thyronine-insulin analogues.

Authors:  Fariba Shojaee-Moradie; Michelle P Y Chan; Micayla A Telfer; Dietrich Brandenburg; Erik Sundermann; Heike Eckey; Jens Kleinjung; Achim Schüttler; Richard H Jones
Journal:  Biochem J       Date:  2004-07-01       Impact factor: 3.857

Review 2.  Dyslipidemia of the metabolic syndrome.

Authors:  Giacomo Ruotolo; Barbara V Howard
Journal:  Curr Cardiol Rep       Date:  2002-11       Impact factor: 2.931

Review 3.  Finding the right route for insulin delivery - an overview of implantable pump therapy.

Authors:  Lia Bally; Hood Thabit; Roman Hovorka
Journal:  Expert Opin Drug Deliv       Date:  2016-12-07       Impact factor: 6.648

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.